pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
pharmadog news

Browse

395 stories matching this filter · ← front page

★ save view↓export CSV
rangeto
sort
recentoldestsourcealpha
source
STAT1566Endpoints1227BioSpace565Fierce Biotech562BioPharma Dive467raps194onclive165fda recalls
therapy area
allOncology10451Rare Disease2758Immunology2463Cardiology2288Hematology1887Pulmonology1875Vaccines
  • Experts discuss practical treatment selection for renal cell carcinoma across risk groups
    A recent educational segment featured Dr. Elizabeth Plimack together with Dr. Sundhar Ramalingam and Dr. Yasser Ged discussing treatment choices for renal cell carcinoma. The conversation centered…
    onclive · 5mo agoNeutral↗ source
  • MimiVax and Roswell Park start Phase 2 trial of SurVaxM with temozolomide for metastatic neuroendocrine tumors
    MimiVax Inc. and Roswell Park Comprehensive Cancer Center announced the launch of a randomized Phase 2 study evaluating SurVaxM in combination with temozolomide for patients with progressing metast…
    onclive · 5mo agoCRLNeutral↗ source
← prev
page 14 of 16
next →
103
fda medwatch93
globenewswire health73
fda press54
1646
Psychiatry & CNS1107
Ophthalmology871
Endocrinology & Metabolism691
Pain656
Nephrology645
  • Real-World Data Highlight Survival Benefit of Rituximab Maintenance After Frontline BR in MCL
    Rituximab following first-line bendamustine demonstrated significant OS and EFS real-world benefits in mantle cell lymphoma.
    onclive · 5mo agoNeutral↗ source
  • Nivolumab added to standard radiation and hormone therapy yields 90% two-year disease control in high-risk prostate cancer
    A Phase 2 trial evaluated the combination of nivolumab with standard radiation and hormone therapy in patients with high‑volume grade group 5 prostate cancer. The study reported a 2‑year freedom f…
    onclive · 5mo agoPositive readoutPositive↗ source
  • OncLive highlights key advances in ovarian, Hodgkin lymphoma, pancreatic, melanoma and myelofibrosis therapies
    The weekly "Five Under 5" roundup from OncLive curates the most notable oncology video content released during the first week of May. It spotlights recent data across a range of cancer types, offer…
    onclive · 5mo agoNeutral↗ source
  • FDA approves zenocutuzumab for previously treated NRG1-fusion cholangiocarcinoma
    The FDA has granted approval for zenocutuzumab to treat patients with previously treated, advanced cholangiocarcinoma that carries an NRG1 fusion. The decision was based on data from the eNRGy stud…
    onclive · 5mo agoApprovalPositive↗ source
  • Antibody-drug conjugates poised to move lung cancer treatment earlier, boosting response rates and targeting brain metastases
    Experts highlight that antibody‑drug conjugates are reshaping non‑small cell lung cancer therapy, moving beyond their traditional role in later‑line settings. The new agents have demonstrated high…
    onclive · 5mo agoPositive↗ source
  • Zongertinib Shows 76% Response Rate in HER2-Mutant NSCLC, Paving Way for Accelerated FDA Approval
    Zongertinib achieved a 76% overall response rate and a median response duration of 15.2 months in treatment‑naïve patients with HER2‑mutant advanced or metastatic non‑small cell lung cancer. The da…
    onclive · 5mo agoApprovalPositive↗ source
  • Capivasertib plus fulvestrant shows numerical overall-survival gain in PIK3CA/AKT1/PTEN-altered advanced breast cancer
    The CAPItello-291 phase III trial enrolled 708 patients with advanced breast cancer and randomized them 1:1 to receive capivasertib (400 mg twice daily on a 4‑on/3‑off schedule) plus fulvestrant, o…
    onclive · 5mo agoPositive readoutPositive↗ source
  • Pimicotinib shows 76% response rate and functional benefits in TGCT phase 3 trial
    Dr. Randall discussed results from the phase 3 MANEUVER trial of the CSF-1 receptor inhibitor pimicotinib in patients with tenosynovial giant cell tumor (TGCT). The data were presented at the 2025…
    onclive · 5mo agoPositive readoutPositive↗ source
  • Biomarker-directed therapies reshape GI cancer treatment, says expert
    In a recent OncLive On Air podcast, host Courtney Flaherty spoke with Dr. Michael J. Pishvaian about the growing role of biomarker-directed strategies in gastrointestinal oncology. Dr. Pishvaian n…
    onclive · 5mo agoNeutral↗ source
  • FDA approves Zenocutuzumab for NRG1 fusion-positive advanced cholangiocarcinoma
    The U.S. Food and Drug Administration has granted approval for zenocutuzumab-zbco, marketed as Bizengri, to treat adult patients with NRG1 fusion‑positive advanced, unresectable or metastatic chola…
    onclive · 5mo agoApprovalPositive↗ source
  • Giants of Cancer Care Unveils 14th Annual Class of Oncology Innovators
    OncLive announced the 14th Annual Giants of Cancer Care inductees, a program that honors oncology leaders whose research, education, mentorship and patient‑focused work have reshaped cancer treatme…
    onclive · 5mo agoPositive↗ source
  • Neoadjuvant immunotherapy gaining favor for metastatic melanoma, says Dr. Sznol
    Dr. Mario Sznol discussed current guidance on using neoadjuvant therapy for patients with advanced melanoma. Patients who have active nodal disease detected by imaging or physical exam are now vie…
    onclive · 5mo agoNeutral↗ source
  • Experts see bispecific antibodies and CAR-T therapies emerging as future options beyond BTK inhibitors for mantle cell lymphoma
    Lore Gruenbaum, PhD, chief scientific officer and senior vice president of research at Blood Cancer United, discussed alternative treatment strategies for mantle cell lymphoma (MCL) that go beyond…
    onclive · 5mo agoPositive↗ source
  • Phase 2 interim data show rezatapopt yields meaningful responses in heavily pretreated ovarian cancer patients with TP53 Y220C mutation
    Alison Schram, MD presented interim results from the PYNNACLE Phase 2 trial of rezatapopt, a selective p53 reactivator, in patients whose tumors carry the TP53 Y220C mutation. The analysis focused…
    onclive · 5mo agoPositive readoutPositive↗ source
  • Combination of danvatirsen and pembrolizumab fails to boost response in first-line metastatic head-and-neck cancer
    The phase II PEMDA-HN trial evaluated adding the STAT3 antisense oligonucleotide danvatirsen to pembrolizumab in patients with untreated recurrent or metastatic head and neck squamous cell carcinom…
    onclive · 5mo agoNegative readoutNegative↗ source
  • Sacituzumab Govitecan-Trastuzumab Combo Shows Low Response in HER2-Positive Metastatic Breast Cancer After T-DXD
    The phase 2 SATEEN trial evaluated sacituzumab govitecan combined with trastuzumab in patients with HER2-positive metastatic breast cancer who had progressed on T-DXD. The study enrolled 27 evalua…
    onclive · 5mo agoNegative readoutNegative↗ source
  • Sevabertinib-related diarrhea in HER2-mutated NSCLC is generally low-grade and manageable, study shows
    The SOHO-01 trial examined the safety of sevabertinib in patients with HER2-mutated non-small cell lung cancer, focusing on treatment-related diarrhea. Diarrhea occurred frequently but was mostly…
    onclive · 5mo agoPositive readoutPositive↗ source
  • Experts discuss managing edema, fatigue and long-term tolerability of antibody-drug conjugates in breast and lung cancer
    The piece concludes a series on antibody-drug conjugates, noting that cumulative toxicities can restrict long-term treatment. Dr. Hope Rugo and Dr. Aaron Lisberg point out that edema and fatigue a…
    onclive · 5mo agoNeutral↗ source
  • OncLive launches weekly quiz covering recent breast, lung and pancreatic cancer updates
    OncLive released its May 8, 2026 weekly news quiz, inviting readers to test their knowledge of recent developments in breast, lung and pancreatic cancers. The quiz highlights several recent oncolo…
    onclive · 5mo agoNeutral↗ source
  • OncLive poll shows oncogene-driven NSCLC as top focus for lung cancer abstracts at ASCO 2026
    OncLive surveyed its LinkedIn and X followers to learn which lung cancer topics will draw the most attention at the 2026 ASCO Annual Meeting in Chicago. The poll asked participants to select the ar…
    onclive · 5mo agoNeutral↗ source
  • Poll Shows Readers Most Excited for PersevERA BC Trial Data at ASCO 2026
    As the 2026 ASCO Annual Meeting draws near, a recent poll asked oncology readers which breast-cancer abstract they are most looking forward to. Respondents could choose among several late-breaking…
    onclive · 5mo agoNeutral↗ source
  • FDA approves relacorilant with nab-paclitaxel for platinum-resistant ovarian cancer
    The FDA has granted approval for the combination of relacorilant and nab-paclitaxel to treat adult patients with platinum‑resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer…
    onclive · 5mo agoApprovalPositive↗ source
  • FDA approves small-molecule dasatinib formulation, expanding CML treatment options
    Dr Michael J. Mauro explained that the FDA gave its nod in November 2025 to a generic, small-molecule version of dasatinib, the drug sold as Sprycel, for adult patients with Philadelphia-positive c…
    onclive · 5mo agoApprovalPositive↗ source